 |
PTC THERAPEUTICS, INC. FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING
May 16, 2013
|
7.1 KB |
| |
South Plainfield, NJ—May 16, 2013—PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not bee...
|
|
PTC THERAPEUTICS APPOINTS MARK ROTHERA AS CHIEF COMMERCIAL OFFICER
Apr 23, 2013
|
7.6 KB |
| |
SOUTH PLAINFIELD, NJ – April 23, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug...
|
|
PTC THERAPEUTICS CLOSES $60 MILLION PRIVATE FINANCING
Mar 7, 2013
|
8.8 KB |
| |
SOUTH PLAINFIELD, NJ - March 7, 2013 - PTC Therapeutics, Inc. (PTC) today announced the successful completion of a $60 million financing led by Brookside Capital Partners Fund, L.P. Joining Brookside as new investors in this financing are Adage Capital Management, Jennison Associates L.L.C. (on behalf of fund clients), Longwood Fund and a...
|
|
PTC THERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR ATALUREN IN DUCHENNE MUSCULAR DYSTROPHY
Dec 6, 2012
|
13.2 KB |
| |
SOUTH PLAINFIELD, NJ - December 6, 2012 - PTC Therapeutics, Inc. (PTC) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) seeking conditional approval for ataluren, an investigational new drug for the treatment of patients with nonsense mutation Duchenne muscular dystr...
|
|
PTC THERAPEUTICS APPOINTS GEOFFREY McDONOUGH, M.D. TO BOARD OF DIRECTORS
Nov 6, 2012
|
7.8 KB |
| |
SOUTH PLAINFIELD, NJ – November 6, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty pharmaceutical company developing therapies ...
|
|
PTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever
Oct 22, 2012
|
8.6 KB |
| |
SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue fever, a mosquito-borne disease that is a ...
|
|
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
Sep 28, 2012
|
7.6 KB |
| |
SOUTH PLAINFIELD, NJ – September 28, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation in Summit, New Jersey. "We are ...
|
|
PTC THERAPEUTICS CLOSES $30 MILLION FINANCING
Jul 23, 2012
|
7.3 KB |
| |
SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing inv...
|
|
PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN WELLCOME TRUST BMI1 COLLABORATION
Jul 11, 2012
|
8.4 KB |
| |
SOUTH PLAINFIELD, NJ – July 11, 2012 – PTC Therapeutics, Inc. (PTC) today announced that it has selected an experimental drug candidate to advance in its BMI1 program for aggressive and drug-resistant tumors. The milestone triggers drawdown of the next $2.3 million installment of its Seeding Drug Discovery Award from the Wellcome Trust....
|
|
PTC THERAPEUTICS INITIATES OPEN-LABEL STUDY FOR ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Jun 27, 2012
|
10.3 KB |
| |
SOUTH PLAINFIELD, NJ – June 27, 2012 – PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior, PTC-sponsored clinical study. The primary objective ...
|
|
Top-Line Data from Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Jun 8, 2012
|
15.5 KB |
| |
SOUTH PLAINFIELD, NJ – June 8, 2012 – PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The results demonstrated positive trends in lung function as measured by FEV1 (forced expiratory volume in one second) and in the...
|
|
PTC THERAPEUTICS ANNOUNCES EXECUTIVE PROMOTIONS
Apr 2, 2012
|
7.5 KB |
| |
SOUTH PLAINFIELD, NJ – April 2, 2012 - PTC Therapeutics, Inc. (PTC) today announced the promotions of Cláudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer."I am extremely pleased to announce these promotions. Cláudia has made significant contributions to the growth and development of PT...
|
|
PTC THERAPEUTICS' ANTIBACTERIAL PROGRAM RECEIVES $5 MILLION AWARD FROM THE WELLCOME TRUST
Dec 22, 2011
|
8.1 KB |
| |
SOUTH PLAINFIELD, NJ – December 22, 2011 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. PTC previousl...
|
|
Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA)
Nov 29, 2011
|
12.1 KB |
| |
Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme. SMA is a genetic neuromuscular disorder that causes muscle weakness. One in every 10,000 children born is affected with the disorder, which currently has no effective treat...
|
|
PTC Therapeutics Receives Grand Challenges Explorations Funding
Nov 7, 2011
|
8.0 KB |
| |
South Plainfield, NJ– November 7, 2011 - PTC Therapeutics, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges. Dr. Zhengxian Gu...
|
|
PTC THERAPEUTICS AND GENZYME ANNOUNCE RESTRUCTURING OF COLLABORATION
Sep 2, 2011
|
9.6 KB |
| |
SOUTH PLAINFIELD, NJ AND CAMBRIDGE, MA – SEPTEMBER 2, 2011 – PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries. Under the restructured agre...
|
|
ATALUREN PHASE 2 DATA IN NONSENSE MUTATION CYSTIC FIBROSIS PUBLISHED IN THE EUROPEAN RESPIRATORY JOURNAL
Jul 1, 2011
|
13.6 KB |
| |
SOUTH PLAINFIELD, NJ – July 1, 2011 – PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted i...
|
|
ASTRAZENECA AND PTC THERAPEUTICS ANNOUNCE STRATEGIC ONCOLOGY DRUG DISCOVERY COLLABORATION WITH POTENTIAL EXTENSION TO OTHER THERAPEUTIC AREAS
Jun 29, 2011
|
9.8 KB |
| |
ALDERLEY PARK, UK and SOUTH PLAINFIELD, N.J., June 29, 2011 – AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and dev...
|
|
PTC THERAPEUTICS APPOINTS ROBERT SPIEGEL, M.D. AS CHIEF MEDICAL OFFICER
Mar 30, 2011
|
8.3 KB |
| |
SOUTH PLAINFIELD, NJ – MARCH 30, 2011 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer. Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough. PTC also announced today the promotion of Jay Barth, M.D. to Vice President of Clinical Development. ...
|
|
PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration with the Wellcome Trust
Mar 2, 2011
|
8.6 KB |
| |
SOUTH PLAINFIELD, NJ – March 2, 2011 – PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The research marks a milestone in PTC's collaboration with the Wellcome ...
|
|
|
